765 related articles for article (PubMed ID: 27367184)
21. Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020).
Chen NN; Zhang H; You QD; Xu XL
Expert Opin Ther Pat; 2021 Jun; 31(6):563-584. PubMed ID: 33459063
[TBL] [Abstract][Full Text] [Related]
22. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
23. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
Corrales L; Gajewski TF
Cytokine; 2016 Jan; 77():245-7. PubMed ID: 26315534
[No Abstract] [Full Text] [Related]
24. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
Ohkuri T; Ghosh A; Kosaka A; Zhu J; Ikeura M; David M; Watkins SC; Sarkar SN; Okada H
Cancer Immunol Res; 2014 Dec; 2(12):1199-208. PubMed ID: 25300859
[TBL] [Abstract][Full Text] [Related]
25. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity.
McAndrews KM; Che SPY; LeBleu VS; Kalluri R
J Biol Chem; 2021; 296():100523. PubMed ID: 33711340
[TBL] [Abstract][Full Text] [Related]
26. STING Signaling in Cancer Cells: Important or Not?
Sokolowska O; Nowis D
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):125-132. PubMed ID: 28748479
[TBL] [Abstract][Full Text] [Related]
27. DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Kitai Y; Kawasaki T; Sueyoshi T; Kobiyama K; Ishii KJ; Zou J; Akira S; Matsuda T; Kawai T
J Immunol; 2017 Feb; 198(4):1649-1659. PubMed ID: 28069806
[TBL] [Abstract][Full Text] [Related]
28. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
29. STING-mediated DNA sensing in cancer immunotherapy.
Zhou X; Jiang Z
Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
[TBL] [Abstract][Full Text] [Related]
30. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
31. Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells.
Miao L; Qi J; Zhao Q; Wu QN; Wei DL; Wei XL; Liu J; Chen J; Zeng ZL; Ju HQ; Luo HY; Xu RH
Theranostics; 2020; 10(2):498-515. PubMed ID: 31903134
[No Abstract] [Full Text] [Related]
32. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
33. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells.
Klarquist J; Hennies CM; Lehn MA; Reboulet RA; Feau S; Janssen EM
J Immunol; 2014 Dec; 193(12):6124-34. PubMed ID: 25385820
[TBL] [Abstract][Full Text] [Related]
34. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1
Tsuchiya N; Zhang R; Iwama T; Ueda N; Liu T; Tatsumi M; Sasaki Y; Shimoda R; Osako Y; Sawada Y; Kubo Y; Miyashita A; Fukushima S; Cheng Z; Nakaki R; Takubo K; Okada S; Kaneko S; Ihn H; Kaisho T; Nishimura Y; Senju S; Endo I; Nakatsura T; Uemura Y
Cell Rep; 2019 Oct; 29(1):162-175.e9. PubMed ID: 31577946
[TBL] [Abstract][Full Text] [Related]
35. SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function.
Hu Z; Teng XL; Zhang T; Yu X; Ding R; Yi J; Deng L; Wang Z; Zou Q
Mol Cell; 2021 Mar; 81(5):940-952.e5. PubMed ID: 33434504
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist.
Zhang X; Liu B; Tang L; Su Q; Hwang N; Sehgal M; Cheng J; Ma J; Zhang X; Tan Y; Zhou Y; Duan Z; DeFilippis VR; Viswanathan U; Kulp J; Du Y; Guo JT; Chang J
ACS Infect Dis; 2019 Jul; 5(7):1139-1149. PubMed ID: 31060350
[TBL] [Abstract][Full Text] [Related]
37. STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Curran E; Chen X; Corrales L; Kline DE; Dubensky TW; Duttagupta P; Kortylewski M; Kline J
Cell Rep; 2016 Jun; 15(11):2357-66. PubMed ID: 27264175
[TBL] [Abstract][Full Text] [Related]
38. TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.
Tani T; Mathsyaraja H; Campisi M; Li ZH; Haratani K; Fahey CG; Ota K; Mahadevan NR; Shi Y; Saito S; Mizuno K; Thai TC; Sasaki N; Homme M; Yusuf CFB; Kashishian A; Panchal J; Wang M; Wolf BJ; Barbie TU; Paweletz CP; Gokhale PC; Liu D; Uppaluri R; Kitajima S; Cain J; Barbie DA
Cancer Discov; 2024 May; 14(5):752-765. PubMed ID: 38227896
[TBL] [Abstract][Full Text] [Related]
39. Feedback activation of CD73-Adenosine axis attenuates the antitumor immunity of STING pathway.
Fu N; Zhang Z; Quan J
Biochem Biophys Res Commun; 2024 May; 708():149814. PubMed ID: 38531218
[TBL] [Abstract][Full Text] [Related]
40. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Rivera Vargas T; Benoit-Lizon I; Apetoh L
Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
